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Immunoglobin-A and the pathogenesis of schistosomal glomerulopa-
thy. Several observations suggest that the evolution of schistosomal
glomerulopathy into clinically overt and progressive disease may involve
pathogenetic mechanisms other than simple glomerular deposition of
parasitic antigens. In a previous study, IgA was suggested to be a mediator
of late glomerular lesions in this disease. This issue is further addressed in
this work. The study includes 32 patients with hepatosplenic schistosomi-
asis, of whom 16 had Overt glomerular involvement, along with four
control groups: (a) 15 healthy volunteers; (b) 15 patients with simple
intestinal mansoniasis; (c) 17 patients with non-schistosomal chronic liver
disease; and (d) 21 subjects with primary nephrotic syndrome not associ-
ated with schistosomiasis. Routine assessment was done for all subjects
including confirmatory tests for schistosomal infection, liver and renal
function tests, hepatitis viral markers and abdominal ultrasonography. The
total serum concentrations of IgG, 1gM, IgA were measured, as well as
their respective circulating immune complexes, rheumatoid factors, anti-
gliadin- and anti-DNA-antibodies. Liver and renal biopsies were obtained
from the relevant groups and studied by light microscopy. Renal biopsies
were also examined by immunofluorescence. Patients with simple intesti-
nal schistosomiasis had a significant increase in 1gM antigliadin antibodies.
Those complicated with hepatosplenic involvement also had a significant
increase in the mean IgG anti-gliadin antibodies, IgG rheumatoid factor
and 1gM anti-DNA activity. Cases further complicated by overt glomeru-
lar disease showed a distinct IgA predominance, mainly expressed in the
serum anti-gliadin antibody pool and anti-DNA activity. This profile was
essentially similar to that observed in control cirrhotics. There was a
significant increase in the frequency of IgA glomerular deposits in renal
biopsies obtained from patients with Overt schistosomal glomerulopathy,
in contrast to control nephrotics. The deposits were mainly mesangial, but
were also encountered in subendothelial, suhepithelial and peritubular
locations. Their frequency was significantly higher with more advanced
lesions as seen by light microscopy. The relevance of these data is
discussed, leading to the following conclusions: (a) serum IgA-anti-gliadin
and -anti-DNA antibodies, and glomerular IgA deposits are markers of
significant renal involvement in patients with hepatosplenic schistosomi-
asis. (b) IgA may be involved in the pathogencsis of advanced glomerular
pathology when superimposed on parasite-induced lesions. (c) There is a
significant increase in serum auto-reactivity in hepatosplenic schistosomi-
asis, which may also have pathogentic implications. (d) Increased produc-
tion by the inflammatory bowel lesions, impaired clearance by the fibrotic
livers and probable switching of immunoglobulin synthesis are suggested
to explain the observed IgA predominance in those who develop renal
complications.
Glomerulonephritis often complicates chronic parasitic infesta-
tions as schistosomiasis, malaria, leishmaniasis, filariasis, eechino-
coccosis, trichinosis, trypanosomiasis and others [1]. The brunt of
glomerular injury is usually mesangial, expressed as cellular
proliferation and matrix expansion in a diffuse or focal pattern [1].
Immune complexes comprising parasitic antigens [2—5} and spe-
cific antibodies [6], mostly composed of 1gM, are usually detected
in the early stages of glomerular pathology. In the majority of
cases, such lesions are either subclinical [7], transient [8, 91 or mild
enough to be overshadowed by the prominent manifestations of
the original illness [10]. Schistosomiasis is one of the few notable
exceptions in that it is often associated with overt features of
glomerular disease including the nephrotic syndrome [111, hyper-
tension [121, urinary abnormalities [131, and progression to
chronic renal failure [14].
The clinicopathologic spectrum of schistosomal glomerulopa-
thy is probably the widest among parasitic nephropathies, ranging
from silent mesangial proliferation to glomeruloselerosis [15].
Little is known about the factors leading to the selection of some
12 to 15% of patients with hepatosplenic schistosomiasis who
progress to clinically overt disease, and further on to ESRD [16].
Certain agent factors are often incriminated, including the para-
site's species and strain, duration of the disease, and probably
certain associated infections. Host factors may even be more
important, including genetic influence, autoimmune reactivity,
and hepatic fibrosis [16]. The latter has attracted the attention of
students in the field over the past three decades, on the basis of
experimental [17—191, clinical [12] and post-mortem [20] observa-
tions. The sovereignty of IgA mesangial deposits in late clinical
[21] and experimental [22] schistosomal glomerulopathy suggests
that this immunoglobulin may he an important mediator of the
"liver effect" in schistosomal glomcrulopathy.
This work was designed to examine such conjecture through
studying the principal forms of circulating IgA in clinically overt
schistosomal glomerulopathy in comparison with appropriately
selected control groups.
Method
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The study includes 101 subjects, comprising two target cohorts
and four control groups (Table 1). The former (Groups I and II)
are composed of all consecutive patients with hcpatosplenic
schistosomiasis presenting to the Out-patient clinics of Cairo
University or the Theodore Bilharz Institute hospitals over one
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Table 1. Study population
Age years
Group Title
Subjects
included Range
Mean
so Female/Male Description
I Hepatosplenic schistosomiasi 16 13—40 29.3 9.03 2/14 Biopsy-confirmed hepatosplenic schistosomiasis without dip-
without proteinuria stick detectable protein on 3 occasions in morning and post-
exercise mid-stream urine samples
II Hepatosplenic schistosomiasis 17 13—48 34.2 8.67 4/13 Biopsy-confirmed hepatosplenic schistosomiasis with
with glomerulopathy clinicopathologic evidence of schistosomal glomerulopathy°
III Healthy controls 15 27—36 31.0 2.75 5/10 Healthy volunteers from medical and paramedical staff
IV Simple schisto 15 13—32 21.0 5.66 0/15 Uncomplicated S. mansoni intestinal schistosomiasis
V Non-schistosomal chronic 17 30—52 39.8 6.16 1/16 No evidence of previous or current infection°
liver disease
VI Primaiy nephrotic syndrome 21
101
15—33 23.2 5.4 8/13
20/81
No evidence of previous or current infection (Table 2).
Details in text
Table 2. Histopathological diagnosis in subjects with primary nephrotic
syndrome
Mesangioproliferative glomerulonephritis 9
Mesangiocapillary glomerulonephritis 6
Minimal change disease 2
Amyloidosis 2
Membranous nephropathy 1
Focal & segmental glomerulosclerosis 1
Total 21
year. The diagnosis was based on: (1) clinical and ultrasono-
graphic [231 evidence of hepatosplenic schistosomiasis; (2) his-
topathologic evidence of periportal fibrosis sparing the lobular
architecture, with or without schistosomal ova or pigments [24];
and (3) detection of S. mansoni ova in the stools or rectal snips.
Group I cases had no dip-stick detectable proteinuria (Table 1),
while those included in Group H had overt proteinuria, with renal
biopsy findings compatible with schistosomal glomerulopathy [151.
Exclusion criteria comprised: (1) evidence of associated urinary
schistosomiasis (hematobiasis); (2) clinical, serological or his-
topathological evidence of associated liver disease, such as viral
hepatitis; (3) evidence of other secondary glomerulopathy; (4)
impaired hepatocellular function; and (5) serum creatinirte above
2 mg/dl.
The control groups (Table 1) comprised: (a) selected healthy
volunteers from the medical and paramedical staff (Group III);
(b) randomly selected patients with confirmed uncomplicated
intestinal schistosomiasis (Group IV); (c) randomly selected
patients with non-schistosomal chronic viral hepatic disease in-
cluding "chronic persistent" hepatitis (3 cases), "chronic active"
hepatitis (6 cases), "active cirrhosis" (4 cases), and established
post-hepatitic cirrhosis (4 cases) (Group V); and (d) contempo-
rary patients with primary glomerulonephritis subjected to routine
renal biopsy (Table 2), provided they had no evidence of past or
present schistosomal infestation (Group VI).
All subjects were clinically assessed, and subjected to routine
laboratory evaluation by standard methodology, which included:
(1) search for evidence of schistosomal infestation by examination
of the urinary sediment, stools analysis and circum-oval precipitin
test. (2) Determination of serum biliruhin, AST and ALT. (3)
Determination of the serum total protein concentration and the
electrophoretic pattern. (4) Testing the serum reactivity for
markers of HBV and HCV. (5) Routine urine examination and
determination of 24-hour urinary protein. (6) Determination of
BUN and endogenous 24-hour creatinine clearance. (7) Ultra-
sonic examination of the abdomen.
The serum profiles of immunogloblins G,A and M were studied
using the following methodology.
Total serum concentrations
These were measured by an ELISA assay [251.
Plates (Nunc Immunoplate I, Roskilde, Denmark) were coated
overnight at +4°C with polyclonal IgG of goat anti-human a, or
y chain (CAPPEL Cochranville PA.) at a concentration of 100
/.Lg/ml in 0.1 M carbonate buffer pH 9.6. Plates were washed with
Titertek Microplate Washer (Flow Laboratories, Irvine, UK).
Sera diluted in 0.05 M phosphate buffer pH 7.3 containing 0.05%
Tween 20 and 0.1% BSA were deposed in triplicate (1/150000 for
IgA, 1/10000 for 1gM, 1/400000 for IgG). After one hour at 37°C,
plates were washed. One hundred microliters of peroxidase
conjugated polyclonal IgG goat anti-human a, ji or y chain
diluted at optimal concentration in phosphate buffer were added
in each well. After incubation and washing, 100 d of substrate
consisting of 4 mtvi orthophenylenediamine (Sigma Chemical Co.,
St. Louis, MO, USA) in 0.02 M citrate phosphate buffer pH 5.0
containing 0.04% (vol/vol) H2O2 were added. Color development
was stopped after 10 minutes with 50 jil HCI 1 N. Absorbanee of
each well was read at 492 nm with a Titertek Multiscan (Flow
Laboratories). IgA, lgG and 1gM concentrations were evaluated
according to a standard curve. Results were expressed in grams
per ml.
Circulating immune complexes
Levels of circulating immune complexes (CIC) containing C3
and IgA, IgG or 1gM were estimated by a solid-phase enzyme-
linked immunosorbent assay [26—29].
Aggregated immunoglobulins. IgA from colostrum or human lgG
were aggregated at a concentration of 10 mg/ml by heating at 63°C
for 150 minutes. Bovine serum albumin (fraction V; Sigma) was
added to all preparations at a final concentration of 0.5% in order
to stabilize the composition of the aggregated immunoglobulins.
Aggregated 1gM were purified from the serum of a patient with
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1gM myeloma by a chromatography on Sephacryl S 300 (Pharma-
cia Sweden). Before use, aggregated IgA and IgG were preincu-
bated for one hour at 37°C with a pooi of normal human sera in
order to fix iC3b [291 and then treated as tested sera.
PEG precipitation. Immune complexes were precipitated from
the sera with PEG 6000. Fifty milliliters of serum were added to
1 ml of 3.8% PEG 6000 (OSI, Paris, France) in phosphate buffer
saline pH 7. After 90 minutes in ice, the precipitates were
centrifuged at 2400 g for 20 minutes and then washed with I ml of
3.5% PEG. After centrifugation, the precipitates were redissolved
in 250 ml of 0.05 M phosphate buffer, pH 7.3, containing 0.05%
Tween 20 and 0.1% BSA.
ELISA assay. Plates were coated overnight with F(ab') 2
fragments of goat IgG antihuman C3 (Capell, Cochranville, PA,
USA) diluted to 10 mg/mI in 0.1 M carbonate buffer, pH 9.6. One
hundred milliliter aliquots of redissolved PEG precipitates were
added to anti-C3 coated wells at a dilution equivalent to 1/100 for
CIC lgA or IgG and 1/200 for CIC 1gM of the original serum.
After one hour at 37°C, plates were washed and 100 ml of
peroxidase conjugated F (ab') 2 fragments goat anti-human a, p.
or y chain (Cappel) were added. Reactions were ended as
described in RF assay (described below). Results were expressed
as a percent of aggregated immunoglobulins.
Serum auto-reactivity
This was assessed by the assay of anti-DNA antibodies and
rheumatoid factor activity.
Anti-DNA antibodies. Samples were screened for the presence
of anti-DNA antibodies by an enzyme-linked immunosorbent
assay [30].
Plates were coated overnight at +4°C with native DNA from
calf thymus (Sigma) at a concentration of 25 mg/ml in 0.1 M
carbonate buffer pH 9.6. After washing, free sites were blocked by
incubation with a 0.2% gelatin solution in carbonate buffer during
one hour at 37°C. Sera diluted at 1/100 for IgA and 1/800 for IgG
and 1gM were deposed in triplicate and incubated one hour at
37°C. Then 100 ml of peroxidase conjugated IgG goat anti-human
a, p. or y chain were added to each well. After washing, OPD was
added and resulting optical density was determined at 492 nm (c.f.
RF assay). Results were expressed as an index.
Rheumatoid factor activity. IgA, lgG and 1gM rheumatoid
factors (RF) were detected by an enzyme-linked immunoassay
[28, 29, 311.
Plates were coated with non-aggregated human IgG (Sigma) at
a concentration of 10 mg/ml in 0.1 M carbonate buffer, pH 9.6, for
1gM and IgA RF and with non-aggregated horse lgG at 10 mg/mI
for IgG rheumatoid factor. After a night at -1-4°C, the plates were
washed with saline buffer containing 0.05% Tween 20. Sera
diluted at 1/100 in 0.05 M phosphate buffer, pH 7.3, containing
0.05% Tween 20 and 0.1% BSA for RF IgA and at 1/400 for FR
IgG and FR 1gM were deposed in triplicate. After one hour at
37°C, the plates were washed and 100 ml of peroxidase conjugated
F(ah') 2 fragments, goat anti-human a, p. or y chain (Cappel)
appropriately diluted were added to each well. Plates were
incubated one hour at 37°C and then exposed to 100 ml of 4 mM
OPD in 0.02 54 citrate phosphate buffer p1-I 5.0 containing 0.04%
(vol/vol) 11202). After HCL addition, absorbance of each well was
read at 492 nm. Sera were tested in the presence of a pooi of
normal sera and a pool of sera containing rheumatoid factor for
each class of immunoglobulin. Results were expressed as an index.
Anti-gliadin antibody assay
This was chosen as a parameter of the intestinal mucosal
immunoreactivity to food antigens. Their value as a marker of
disease activity in chronic inflammatory bowel disease is con-
firmed [321.
Antigliadin antibodies were measured by an ELISA technique
[32]. Plates were coated with a gliadin at 10 mg/ml in carbonate
buffer, pH 9.6, overnight at +4°C. Sera diluted at 1/50 for IgA,
1/100 for IgG, and 1/200 for 1gM were deposed in triplicate. After
one hour at 37°C, plates were washed and peroxidase conjugated
goat IgG anti-human a, p. or y chain were added. After incubation
(1 hour at 37°C), 100 ml of substrate (OPD as for DNA assay)
were added for 10 minutes at room temperature. Color develop-
ment was stopped with 50 ml HC1 I N. All sera were tested in the
presence of a pool of normal sera and a pooi of sera containing
IgA, IgG, or 1gM anti-gliadin. Results were expressed as an index.
For all these methods, the sera were tested in the presence of
positive sera and negative sera. Positivity threshold was calculated
from the results of 14 patients belonging to Group V, being
defined as mean +2 standard deviation.
Unless contra-indicated, a percutaneous liver biopsy was ob-
tained from Groups 1, II and V. Paraffin sections were prepared,
stained by hematoxylin and eosin and orsin stains, and examined
by light microscopy.
Percutaneous renal biopsy was obtained from Groups II and
VI. Paraffin sections were prepared, stained by hematoxylin and
eosin, PAS, Masson trichrome, silver and Congo red stains, and
examined by light microscopy and when necessary under polarized
light. Frozen sections were treated by fluorescin-labeled antisera
for IgG, 1gM, IgA, C3, fibrinogen and control albumin, and
examined by immunofluorescence.
All data were subjected to statistical analysis using Student's
t-test, paired t-test and analysis of variance.
Results
The two target groups, (Groups I and II) were neatly matching
as regards age and gender distribution, clinical parameters and
liver functions. Patients with associated glomerulopathy (Group
II) had proteinuria ranging from 0.2 to 10.0 (mean 5.2, SD 3.16)
g/24 hrs; 11.7% were hypertensive, and their creatinine clearances
ranged from 39.2 to 106.8 mI/mm with a mean of 73.74 25.00
ml/min compared to 103.4 24.24 mI/mm in those without
dip-stick detectable proteinuria (P < 0.001).
They also generally matched with the control groups as regards
age and gender. Yet, patients with uncomplicated intestinal
schistosomiasis and those with primary nephrotic syndrome were
significantly younger, and the relative contribution of females was
higher in the latter group (Table 1). Group V (non-schistosomal
chronic liver disease) had significantly higher serum bilirubin
(mean 1.52 1.71 mg/dl compared to 0.68 0.22 mgldl and
0.76 0.38 mg/dl in Groups I and II, respectively) and hepatic
transaminases (AST 31.05 19.84 lU/liter compared to 16.56
7.08 and 17.00 12.07 lU/liter, respectively; ALT 30.52 20.03
lU/liter compared to 12.68 5.64 and 13.64 6.39 lU/liter.
respectively). None of Group V patients was hypertensive or
proteinuric, and their renal function was normal (mean creatinine
clearance 91.67 mI/rn in). Group VI (those with primary nephrotic
syndrome) had a marginally higher protein excretion compared to
Group II cases (6.7 4.8 vs. 5.2 3.16 g/24 hr, respectively). They
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Table 3. Concentrations and proportional contributions of total serum immunoglobulins, circulating immune complexes and rheumatoid factors
Total serum concentration giliter
IgA
IgG
1gM
Circulating immune complexes
%
IgA
IgG
1gM
Rheumatoid factors (Index)
IgA
IgG
1gM
Antigliadin antibodies (Index)
IgA
IgG
1gM
Anti-DNA antibodies (Index)
IgA
IgG
1gM
3.07 0.81 3.53 1.43 <0.030 2.72 0.60 2.76 0.53
24.13 2.52 <0.001 21.47 8.19 19.24 3.20 20.08 2.82
2.96 0.61 <0.001 2.96 0.53 <0.001 2.38 0.29 2.61 0.54
25.68 19.55 <0.006 29.73 22.09 <0.002 11.26 6.51 12.20 6.02
37.25 20.50 <0.001 34.53 26.80 <0.010 16.86 6.88 15.86 5.69
26.56 11.48 <0.009 24.20 12.69 <0.010 15.40 5.24 17.66 7.81
19.62 12.98 23.33 14.92 17.13 11.80 11.80 4.93
35.00 12.45 <0.010 35.13 14.30 <0.020 24.06 7.42 22.73 7.64
38.43 16.54 50.26 29.58 32.93 33.99 36.93 18.12
1.76 2.09 4.83 7.75 <0.040 1.23 0.74 1.14 0.65
1.34 1.18 3.60 7.55 1.11 0.94 0.78 0.78
1.82 0.85 <0.040 1.73 0.79 1.35 0.50 1.46 0.56
3.76 1.13 <0.002 2.92 0.88
24.78 3.38 <0.001 17.95 4.71
3.09 0.60 <0.001 3.05 94.00 <0.006
35.93 22.37 <0.001 15.71 835 <0.050
43.68 26.95 <0.001 18.47 14.14
28.50 18.56 <0.007 19.95 10.71
31.81 18.36 <0.007 17.57 12.54
38.25 15.10 <0.004 26.14 13.19
51.87 21.91 <0.004 40.19 21.90
3.70 4.76 <0.030 1.88 1.44
2.16 1.82 <0.030 1.96 2.56
1.93 1.03 2.00 0.90
Fig. 1. Glomerular immunoglobulin deposits in
Group II patients, seen by immunofluorescence.
(a) 1gM mesangial deposits in an early case
(Class I) of schistosomal glomerulopathy. (b)
IgA mesangial and sub-endothelial deposits in
an advanced case (Class III).
were also insignificantly less often hypertensive (4.7% compared
to 11.7%). Their mean creatinine clearances were matching
(means 71.21 24.34 and 73.74 25.00 mI/mm, respectively).
As shown in Table 3, there was a polyclonal increase in the total
serum immunoglobulin concentrations reaching statistically sig-
nificant levels for IgG and 1gM in Group 1, IgA and 1gM in Group
II, and all three immunoglohulins in Group V. Circulating im-
mune complexes of all immunoglobulin classes addressed were
also significantly increased in the mentioned three groups.
In addition, there was a significant selective increase in IgG and
1gM anti-gliadin antibodies, IgG rheumatoid factor and 1gM
anti-DNA antibody activity in Group I. This pattern was carried
over, but modified in favor of IgA, to Group II where a 442%
increase in the mean IgA anti-gliadin antibodies (compared to
normal controls, P < 0.03), and a shift of anti-DNA antibody
activity to IgA (393% compared to normal controls, P < 0.04), at
the expense of 1gM, were observed (Figs. 1 and 2). IgA predom-
inance was even more pronounced in Group V, where the rise of
mean IgA anti-gliadin antibodies reached 904% (P < 0.005), and
that of IgA anti-DNA activity 301% (P < 0.03) at the expense of
1gM. A significant increase in rheumatoid factor activity including
that of IgA (186%), IgG (159%) and 1gM (158%) was also noticed
in this group.
The only significant change observed in Group IV was a 157%
increase in the mean 1gM anti-gliadin antibodies (P < 0.003). The
changes observed in Group VI were variable, reflecting the
diversity of etiology.
There was a statistically significant increase in the frequency of
Group I Group II Group III Group IV Group V Group VI
Mean SD P Mean SD P Mean SD Mean SD P Mean SD P Mean SD P
2.73 2.29 7.16 10.85 <0.030 1.62 0.85 1.85 2.42 14.64 18.15 <0.005 2.88 2.69
2.50 1.64 <0.006 3.22 2.43 <0.003 1.30 0.54 1.12 0.90 4.14 3.74 <0.003 1.18 0.85
1.53 0.56 <0.008 2.00 0.84 <0.001 1.10 1.80 1.73 0.73 <0.003 2.15 1.83 1.64 1.38 <0.010
Target groups are: I, hepatosplenic schistosomiasis, no proteinuria; and II, hepatosplenic schistosomiasis, glomerulopathy. Control groups are: III,
normal volunteers; IV, uncomplicated intestinal schistosomiasis; V, non-schistosomal chronic liver disease; VI, primary nephrotic syndrome.
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interleukin release in the schistosomal granuloma may have
important reflections on the surrounding macrophages and lym-
phoid aggregations.
The hepatic lesions are basically the same. Granulomata de-
velop around metastatic ova in the portal tracts, ending up with
fibrosis and pre-sinusoidal portal hypertension. The hepatocytes
are spared from the direct effects of the granulomatous lesions,
though they may be involved in the subsequent autoimmune
reactions associated with schistosomiasis [42—45]. The hepatic
macrophages, on the other hand, are down-regulated by parasitic
antigens [43] and late cytokines released in the schistosomal
granulomata [40, 411.
The glomerular lesions, in contrast to the mucosal and the
hepatic, are attributed to the adult worm antigens [35—37].
Escaping clearance by the inhibited hepatic macrophages [46], the
latter are deposited in the mesangium leading to a proliferative
response, which has been well documented in many experimental
animals [47] and humans [15] infected with any of the major
species of human-pathogenic schistosomes. Progression into gb-
merulosclerosis, however, has been mainly described in S. man-
soni infection [14, 481, and is usually associated with significant
hepatic fibrosis [12, 14, 16, 20, 21, 36].
Based on experimental data in mice [22, 49] and clinical
observations in humans [21, 36], IgA was suggested to be a
potential mediator in the progression of the glomerular lesions in
schistosomiasis. This hypothesis is further examined in the present
work.
Two subsets of patients with hepatosplenic schistosomiasis,
without and with clinically overt renal involvement (Groups 1 and
2, respectively) constitute the target groups. Since the study
parameters are potentially vulnerable to all the major players in
the scene, that is, the parasite, the liver and the glomerulus, the
independent influence of each of these variables was envisaged
through a selected control patient cohort (Groups IV, V and VI,
respectively).
The total serum immunogbobulin concentrations in our normal
controls (Group III) was a bit higher than expected, which is a
fairly common observation among normal Egyptians (Genin,
unpublished data), often attributed to their frequent exposure to
infections and other antigens in the environment.
Control subjects with chronic non-schistosomal liver disease
(Group V) displayed the usual polyclonal immunoglobulin re-
sponse reported in many previous studies. The IgA predominance
noticed in this group also conforms with previous observations,
being attributed to its impaired hepatic clearance [50—52] and
possibly to increased generation by the gut mucosa [51, 52]. The
same mechanisms may explain the remarkable increase in the
levels of circulating immune complexes observed in this group.
Despite the remarkable elevation of different forms of serum lgA
antibodies, no patient in this group showed any clinical evidence
of renal disease. Since renal biopsy was not undertaken in this
group for ethical reasons, we cannot exclude the occurrence of
subclinical lesions. It is notable, though, that lesions reported in
similar cohorts are usually mild and have limited clinical sequelae
[53, 51.
Control subjects with non-schistosomal nephrotic syndrome
(Group VI) had variable immunoglobulin profiles compatible
with etiology. It is remarkable, however, that none had any
glomerular IgA deposits, which confirms other reports emphasiz-
ing the rarity of IgA nephropathy in African populations [11.
Group V: Non-schistosomal
chronic liver disease
Groups
Ill, IV
Group II:
Schistosomal
nephropathy
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ControljnephroticsI
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Fig. 2. Llrinaty 24-hour proteins in relation to serum anti-gliadin IgA (means
and standard errors) in the different groups.
IgA deposits (Fig. ib) in Group II cases, compared with control
nephrotics (Group VI). Within the former, IgA deposits were
encountered, usually along with other immunoglobulins and com-
plement, in 70% of the biopsies showing more advanced lesions
(AFRAN [331 Classes III to V) compared to 29% in milder forms
of schistosomal gbomerubopathy (Classes I and II), (Table 4). The
deposits were most often mesangial, but subendothelial and
extramembranous deposits were also noticed in 29 and 18% of
cases, respectively, again mostly seen in AFRAN Class III cases.
In contrast, 1gM mesangial deposits were significantly more often
encountered in early (Classes I and II) lesions.
Discussion
Three partners interact in the pathogenesis of schistosomal
gbomerulopathy: the parasite, the liver and the gbomerulus. The
parasite is a blood fluke that inhabits the portal vein, into which it
pours a large load of antigens, mostly originating in its alimentary
canal [34]. A number of these antigens have been clearly identi-
fied in the gbomeruli of experimental animals and patients with
schistosomal gbomerulopathy [35—37]. Parasitic ova are laid in the
cobonic submucosa, where they trigger a chronic granubomatous
reaction to soluble antigens that diffuse into the surroundings via
micropores in the egg shells [38]. The initial phases of the
schistosomal granuloma are largely mediated by Th1 cytokines.
The subsequent release of Th2 cytokines, particularly IL-b and
IL-4 [39—411, is important in checking the intensity of the local
reaction and consequently the local pathology. The array of
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Table 4. Glomerular histopathology and immunofluorescence findings in patients with established schistosoal glomerulopathy compared with those
with the primary nephrotic syndrome
Case number Light microscopy
AFRAN
class
IgA deposits 1gM
eposits d
IgG
eposits
C3
deposits
Fibrin
depositsTotal Mesangial Subendothelial Subepithelial d
1 Minimal change
2 Minimal change
6 Minimal change
7 Axial mesangioproliferative
3 Axial mesangioproliferative
15 Axial mesangioproliferative
17 Exudative
Ia
Ia
Ia
Ic
Ic
Ic
II
—
—
—
—
+
+
—
—
—
—
—
+
—
—
—
—
—
—
—
+
—
—
—
—
—
—
—
—
+
+
+
+
+
+
+
—
+
—
+
—
+
—
+
+
+
—
+
+
—
—
—
—
—
—
—
+
8 Mesangiocapillary (type I)5 Mesangiocapillary (type I)
4 Mesangiocapillary (type I)
9 Mesangiocapillary (type I)
11 Mesangiocapillary (type I)
10 Mesangiocapillary (type I)
with crescents
13 Mesangiocapillary (type
III)
16 Mesangiocapillary (type
III)
12 Mesangiocapillary (type
III)
14 Amyloid
lila
lila
lila
lila
lila
lila
IlIb
Ilib
IlIb
V
—
—
+
+
+
+
+
+
+
—
—
—
—
+
+
+
+
—
+
—
—
—
+
+
+
—
—
+
—
—
—
—
—
—
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Overall frequency (N = 17)
Frequency in Classes I and II (N = 7)
Frequency in Classes 111—V (N = 10)
9 53%
2 29%
7 70%
6
1
5
35%
14%
50%
5 29%
1 14%
4 40%
3
0
3
18%
0%
30%
11
7
3
65% 9 53%
100% 3 43%
30% 5 50%
10 59%
5 71%
4 40%
6 35%
1 14%
4 40%
Frequency in control primary nephrotics (N =21) 0 0% 0 0% 00% 0 0% 7 33% 6 29% 210% 5 24%
The only statistically significant finding in patients with simple
intestinal schistosomiasis (Group IV), was the increased serum
IgM-antigliadin antibodies. This may reflect the local immune
response to food antigens [32, 55], as a consequence of mucosal
macrophage inhibition in schistosomiasis [43, 56, 571. The pre-
dominantly 1gM response is probably the expression of the known
response to many parasitic infestations [58], including schistoso-
miasis [39, 59].
The same finding was carried over into the later phase of
disease evolution, namely hepatosplenic schistosomiasis (Group
I). Yet the spectrum of serum reactivity was wider, depicting two
additional features known about the disease, namely autoimmu-
nity [42—45] and hepatic fibrosis [60, 61]. The former was ex-
pressed in this group by a significant increase of serum IgG
rheumatoid factor and 1gM-anti-DNA activity, while the latter
was displayed by a polyclonal increase in serum total immuno-
globulins and a significant increase of circulating immune com-
plexes [46, 60, 61].
Switching from the parasite-associated 1gM predominance to
the liver-geared IgA sovereignty distinguished patients with overt
glomerular disease (Group II) from those without (Group I). The
former had a statistically significant multitudinous increase in IgA
anti-gliadin and anti-DNA antibodies. IgA glomerular deposits
were noticed in as many as 53% of cases, compared to none in the
control primary nephrotics. Unfortunately, it is impossible to
obtain a respective figure for comparison with Group I patients,
from whom renal biopsies could not obtained for ethical reasons.
However, on the basis of previous observations by some of us [21,
62], such patients are very unlikely to have any igA deposits.
Furthermore, it was noticed in the present study that even within
Group II patients, IgA deposits were far less often associated with
mild glomerular lesions (29% with Classes I and II compared with
70% in Classes III to V). These figures are higher than those
reported in other series [631; the discrepancy is presumably
attributed to variance in the prevalence and severity of associated
hepatic fibrosis in different cohorts.
According to these data and others on primary IgA nephropa-
thy [64], it seems obvious that significant IgA glomerular patho-
genicity requires a co-morbidity factor that is provided, in our
case, by concomitant exposure to schistosomal antigens. It is
understandable that the initial parasite-associated proliferative
lesions may be associated with critical mesangial modulation
necessary for igA binding and/or pathogenicity [65—67].
On the basis of the present findings, we can only speculate
about the mechanisms involved in switching of some patients with
hepatosplenic schistosomiasis to the IgA-predominant immuno-
globulin profile, and hence developing serious renal disease (Fig.
3). Previous studies had suggested that critical impairment of
hepatic clearance may be an important factor [21], and yet this
alone does not explain the disproportionate increase in the
anti-gliadin and anti-DNA fractions. The significant increase in
serum anti-gliadin IgA is suggestive of augmented mucosal gen-
eration, as described in celiac disease, which is also characterized
by chronic gut mucosal inflammation [32]. Switching of the
predominant anti-DNA activity from 1gM to IgA may point to a
corresponding B-lymphocyte switching analogous to that sug-
gested in primary IgA nephropathy [68—71]. Although we have no
cellular data to support this concept, we must admit that the
mucosal scene in hepatosplenic schistosomiasis is optimally set for
switching: a persistent antigen load [32], macrophage inhibition
[66] and Th2 cytokine predominance particularly involving IL-lu
[72, 73]. Committed mucosal immunoblasts could then migrate
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Fig. 3. Suggested pathogenetic mechanisms in schistosomal glomendopathy showing the possible immunological interaction between worms in the portal
blood and egg-granulomata in the liver and colonic submucosa. The potential role of IgA within this context is highlighted.
along with the augmented lymphatic flow, known for chronic liver
disease [74] and particularly for hepatosplenic schistosomiasis
[75], into distant locations, thereby exerting a systemic effect.
It is unclear whether the prominent serum autoreactivity ob-
served in patients with hepatosplenic schistosomiasis has an
independent pathogenetic role in the development or evolution of
the glomerular lesions. It also remains to be elucidated whether
such reactivity contributes to impairment of hepatocyte-depen-
dent IgA clearance via asialoglycoprotein receptors [76], as de-
scribed in other immune-mediated chronic liver disease [77, 78].
To conclude, this work substantiates the importance of hepatic
dysfunction in the progression of schistosomal glomerulopathy.
The critical difference between patients with hepatosplenic schis-
tosomiasis who develop overt nephropathy and those who do not
is the acquisition of the IgA-dominated "hepatic' immunoglobulin
profile. The initial parasite-induced lesions seem to induce the
glomerular mesangium for subsequent IgA-mediated progression.
Parasite-triggered auto-immune mechanisms may be co-pathoge-
netic.
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